The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Seminar Title
Keynote 3 – Exploring the future of pharmacotherapy
Affiliation
Dutch Medicines Evaluation Board
Country
The Netherlands
1. Current Status, Position
Prof. Dr. Leufkens (PharmD, PhD) is Chair of the Dutch Medicines Association Board (MEB) and professor of pharmacoepidemiology at Utrecht University.
2. Education
Prof. Dr. Leufkens obtained his PharmD and PhD degree from Utrecht University. During the mid-80s he worked at Leiden University and was a Fulbright Fellow at the University of Minnesota (US). In 1997 he was appointed as full professor of Pharmacoepidemiology at Utrecht University. From 2003-2005 he was the Scientific Director of the Utrecht Institute for Pharmaceutical Sciences (UIPS), and during 2006-2007 Head of the Depart-ment of Pharmaceutical Sciences of the Faculty of Science in Utrecht. In 2007 he was appointed as Chair of Dutch Medicines Evaluation Board (MEB).
3. Research Area
Prof. Dr. Leufkens is research and policy-wise active at several (inter)national platforms on pharmacoepidemiology (e.g. past co-opted member for pharmacoepidemiology of the EMA CHMP 2009-2015, past-President of ISPE), pharmacovigilance (past-member EMA Pharmacovigilance Working Party), orphan drugs (past-Chairman of the Dutch Steering Committee on Orphan Drugs), pharma policy (since 2008 Scientific Director of the Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation), regulatory science and scenario planning. He is (co) author of >450 papers in peer reviewed journals, book chapters and research reports.
4. Conflcit of interest: none